Related Experiment Video
Updated: Mar 23, 2026

Robotic Enucleation of an Intra-Pancreatic Insulinoma in the Pancreatic Head
Published on: January 3, 2020
Medical Management of Pancreatic Neuroendocrine Tumors: Current and Future Therapy
Jennifer A Chan1, Matthew H Kulke1
1Department of Medical Oncology, Dana-Farber Cancer Institute, Dana 1220, 450 Brookline Avenue, Boston, MA 02215, USA.
Abstract:
When diagnosed at an early stage, resection of pancreatic neuroendocrine tumors (NETs) is often curative. Unfortunately, curative surgery is rarely an option for patients with metastatic disease. Multiple options are available for the management of patients with advanced pancreatic NETs, including surgery, liver-directed therapy, and systemic therapies. Because of the heterogeneity of disease biology and presentation, a multidisciplinary approach to management is critical. Treatment with somatostatin analogs, sunitinib, everolimus, and alkylating agents provide effective systemic therapeutic options for patients. Future studies to evaluate the optimal timing, sequence, and combination of therapies, as well as to identify predictors of response, are warranted.
Insights
For advanced pancreatic neuroendocrine tumors (NETs), early resection offers a cure. Management of metastatic NETs requires a multidisciplinary approach, utilizing surgery, liver-directed, and systemic therapies like somatostatin analogs.
Area of Science:
- Oncology
- Gastroenterology
- Endocrinology
Background:
- Pancreatic neuroendocrine tumors (NETs) are rare neoplasms with variable clinical behavior.
- Early-stage diagnosis and surgical resection offer curative potential for pancreatic NETs.
- Metastatic disease often precludes curative surgical options, necessitating alternative management strategies.
Purpose of the Study:
- To review current management options for advanced pancreatic neuroendocrine tumors (NETs).
- To emphasize the importance of a multidisciplinary approach in treating heterogeneous NET presentations.
- To highlight available systemic therapies and areas for future research.
Main Methods:
- Literature review of therapeutic options for advanced pancreatic NETs.
- Synthesis of data on surgical, liver-directed, and systemic treatments.
- Discussion of disease heterogeneity and the need for personalized treatment strategies.
Main Results:
- Multiple therapeutic modalities exist for advanced pancreatic NETs, including surgery, liver-directed therapies, and systemic agents.
- Somatostatin analogs, sunitinib, everolimus, and alkylating agents are established systemic treatment options.
- A multidisciplinary approach is crucial due to the diverse biology and presentation of pancreatic NETs.
Conclusions:
- Effective management of advanced pancreatic NETs relies on a combination of treatment modalities.
- Further research is needed to optimize treatment sequencing, combinations, and identify response predictors.
- Personalized therapeutic strategies are essential for improving outcomes in patients with advanced pancreatic NETs.
Related Concept Videos
Chronic Pancreatitis II: Collaborative Care
Assessment:
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Acute Pancreatitis II: Clinical Manifestations and Management
Targeted Cancer Therapies
There are several types of targeted therapies against...
Tumor Immunotherapy

